Corrigendum to: Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) (Diabetes, Obesity and Metabolism, (2018), 20, 3, (520-529), 10.1111/dom.13103);Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

Diabetes, Obesity and Metabolism

Volumn 20, Issue 3, 2018, Pages 520-529

  Rosenstock, Julio ^a   Frias, Juan ^b   Páll, Dénes ^c   Charbonnel, Bernard ^d   Pascu, Raluca ^e   Saur, Didier ^e   Darekar, Amanda ^f   Huyck, Susan ^g   Shi, Harry ^e   Lauring, Brett ^g   Terra, Steven G ^e  

^a Dallas Diabetes and Endocrine Center at Medical City   (United States)

^b NATIONAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITÉ DE NANTES   (France)

^e PFIZER INC   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

bone mineral density; ertugliflozin; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ERTUGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; MAGNESIUM; METFORMIN; PHOSPHATE; PLACEBO; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; ANTIDIABETIC AGENT; FUSED HETEROCYCLIC RINGS; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POLLAKISURIA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; ADMINISTRATION AND DOSAGE; BLOOD; BODY WEIGHT LOSS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BONE DENSITY; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 85030632365     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13533     Document Type: Erratum

References (29)

1. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6:e009417.
2. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–794.
3. Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011;54:2952–2960.
4. Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591–598.
5. Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805–808.
6. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721–728.
7. Lauring B, Eldor R, Liu J, et al. Efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus inadequately controlled on the dual combination of metformin and sitagliptin: the VERTIS SITA2 trial. Diabetologia. 2016;59(suppl 1):S93 (abstract 181).
8. Eldor R, Pratley R, Golm G, et al. Effect of ertugliflozin plus sitagliptin on glycemic control vs. either treatment alone in subjects with T2DM inadequately controlled with metformin. American Diabetes Association 76th Scientific Sessions; June 10–14, 2016; New Orleans, LA. abstract 125-LB.
9. American Diabetes Association. Executive summary: standards of medical care in diabetes – 2016. Diabetes Care. 2016;39(suppl 1):S1–S112.
10. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
11. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The consensus committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996;46:1470.
12. Borges JL, Bilezikian JP, Jones-Leone AR, et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients. Diabetes Obes Metab. 2011;13:1036–1046.
13. Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ser B. 2000;62 (Series B, pt 1):134–148.
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213–226.
15. Scheerer MF, Rist R, Proske O, Meng A, Kostev K. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metab Syndr Obes. 2016;9:337–345.
16. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411–419.
17. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–478.
18. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28:1167–1171.
19. Janssen Pharmaceuticals Inc. Invokana® (canagliflozin). Highlights of prescribing information. https://www.invokana.com/prescribing-information.pdf. Accessed March 20, 2017.
20. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
21. Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38:1299–1313.
22. Wanner C, Toto R, Gerich J, et al. No increase in bone fractures with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM). J Am Soc Nephrol. 2013;24(suppl):abstract TH-PO452.
23. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44–51.
24. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
25. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K, Meininger G. Efficacy and safety of canagliflozin (CANA), a sodium glucose cotransporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus. Diabetologia. 2012;55(suppl 1):S315 (abstract 765).
26. Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–999.
27. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
28. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380.
29. Kalra S, Singh V, Nagrale D. Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review. Adv Ther. 2016;33:1502–1518.